Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2021

View Archived Issues

JDQ-443: a mutant-selective, irreversible inhibitor of KRAS G12C with an unprecedented binding mode

miR-7-5p and miR-375-3p: new circulating markers of pituitary NETs

2,3-Disubstituted pyridine IDO1 inhibitors with improved drug-like properties

Thymic stromal lymphopoietin and T cells shown to homeostatically regulate sebum production

Study identifies cell state as oncogene enabler

AMMS patents carbonic anhydrase inhibitors

Bristol Myers Squibb presents PADI4 inhibitors

Haim Bio synthesizes new antiepileptics

Stingray Therapeutics presents new ENPP1 inhibitors

AstraZeneca discloses adenosine receptor antagonists

Variants in PI4KA linked to severe neurometabolic disorder

New kratom derivatives identified with mu-opioid receptor modulatory activity

Deficient H2A.Z deposition tied to uterine leiomyoma

Celsion reports in vivo data on PLACCINE DNA vaccine platform against SARS-CoV-2

QGC-606 prevents LV dysfunction in mice post-MI

LEO Pharma's novel IL-17A/IL-17AR interaction modulator for the oral treatment of psoriasis

New FPR2 agonists target inflammation in Alzheimer's disease

Discovery and preclinical characterization of novel cyclic dinucleotide STING agonists

SymBio collaborates with NCCS to explore use of brincidofovir in EBV-positive lymphoma

SBIR grant supports Felix Biotechnology's work on engineering bacteriophage

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...